These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 27618975)

  • 21. Comparative effectiveness of direct oral anticoagulants versus low-molecular weight heparins for the prevention of venous thromboembolism after total hip or knee replacement: A nationwide database cohort study.
    Blin P; Samama CM; Sautet A; Benichou J; Lignot-Maleyran S; Lamarque S; Lorrain S; Lassalle R; Droz-Perroteau C; Mismetti P; Moore N
    Pharmacol Res; 2019 Mar; 141():201-207. PubMed ID: 30583081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results.
    Wells PS; Lensing AWA; Haskell L; Levitan B; Laliberté F; Durkin M; Ashton V; Xiao Y; Crivera C; Lejeune D; Schein J; Lefebvre P
    J Med Econ; 2018 Jun; 21(6):587-594. PubMed ID: 29469638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry.
    Bauersachs R; Agnelli G; Gitt AK; Monreal M; Mismetti P; Willich SN; Laeis P; Fronk EM; Bramlage P; Cohen AT;
    Thromb Res; 2017 Sep; 157():181-188. PubMed ID: 28780343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticoagulation monitoring by an anticoagulation service is more cost-effective than routine physician care.
    Aziz F; Corder M; Wolffe J; Comerota AJ
    J Vasc Surg; 2011 Nov; 54(5):1404-7. PubMed ID: 21741791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initiation of direct oral anticoagulants versus warfarin for venous thromboembolism: impact on time to hospital discharge.
    Basto AN; Fewel NP; Vo K; Stock EM; Ta M
    J Thromb Thrombolysis; 2018 Jan; 45(1):51-55. PubMed ID: 29086244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of Direct Oral Anticoagulants Versus Traditional Therapies for Acute Venous Thromboembolism After Direct Discharge From the Emergency Department or After Hospitalization: An Audit of 16 Canadian Hospitals.
    Bungard TJ; Ritchie B; Bolt J; Thomson P; Semchuk WM
    Clin Ther; 2020 May; 42(5):873-881. PubMed ID: 32284189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.
    Lefebvre P; Coleman CI; Bookhart BK; Wang ST; Mody SH; Tran KN; Zhuo DY; Huynh L; Nutescu EA
    J Med Econ; 2014 Jan; 17(1):52-64. PubMed ID: 24156243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patterns and Predictors of Use of Anticoagulants for the Treatment of Venous Thromboembolism Following Approval of Rivaroxaban.
    Dault R; Vanasse A; Blais L; Perreault S; Farand P; Le Templier G; Beauchesne MF
    Clin Appl Thromb Hemost; 2016 Nov; 22(8):765-771. PubMed ID: 26467323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs.
    Caprini JA; Tapson VF; Hyers TM; Waldo AL; Wittkowsky AK; Friedman R; Colgan KJ; Shillington AC;
    J Vasc Surg; 2005 Oct; 42(4):726-33. PubMed ID: 16242561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain.
    Muñoz A; Gallardo E; Agnelli G; Crespo C; Forghani M; Arumi D; Fernández de Cabo S; Soto J
    J Med Econ; 2022; 25(1):840-847. PubMed ID: 35703036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population.
    Wells PS; Prins MH; Beyer-Westendorf J; Lensing AWA; Haskell L; Levitan B; Laliberté F; Ashton V; Xiao Y; Lejeune D; Crivera C; Lefebvre P; Zhao Q; Yuan Z; Schein J; Prandoni P
    Chest; 2018 Dec; 154(6):1371-1378. PubMed ID: 30201406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health care expenditures and therapeutic outcomes of a pharmacist-managed anticoagulation service versus usual medical care.
    Hall D; Buchanan J; Helms B; Eberts M; Mark S; Manolis C; Peele P; Docimo A
    Pharmacotherapy; 2011 Jul; 31(7):686-94. PubMed ID: 21923456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment, monitoring, and economic outcomes of venous thromboembolism among hospitalized patients in China.
    Wu EQ; Xie J; Wu C; Du EX; Li N; Tan R; Liu Y
    Pharmacoeconomics; 2014 Mar; 32(3):305-13. PubMed ID: 24500859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective.
    Seaman CD; Smith KJ; Ragni MV
    Thromb Res; 2013; 132(6):647-51. PubMed ID: 24139508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical characteristics and treatment patterns of patients with venous thromboembolism (VTE) transitioning from hospital to post-discharge settings.
    Burton T; Hlavacek P; Guo JD; Rosenblatt L; Mardekian J; Ferri M; Russ C; Kline JA
    Hosp Pract (1995); 2020 Oct; 48(4):196-205. PubMed ID: 32720816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
    Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
    J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status.
    Weeda ER; Peacock WF; Fermann GJ; Baugh CW; Wells PS; Ashton V; Crivera C; Wildgoose P; Schein JR; Coleman CI
    Int J Clin Pract; 2017 Jan; 71(1):. PubMed ID: 28097761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK.
    Jugrin AV; Ustyugova A; Urbich M; Lamotte M; Sunderland T
    Thromb Haemost; 2015 Oct; 114(4):778-92. PubMed ID: 26272227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A cost-analysis model for anticoagulant treatment in the hospital setting.
    Mody SH; Huynh L; Zhuo DY; Tran KN; Lefebvre P; Bookhart B
    J Med Econ; 2014 Jul; 17(7):492-8. PubMed ID: 24773068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immediate Discharge and Home Treatment With Rivaroxaban of Low-risk Venous Thromboembolism Diagnosed in Two U.S. Emergency Departments: A One-year Preplanned Analysis.
    Beam DM; Kahler ZP; Kline JA
    Acad Emerg Med; 2015 Jul; 22(7):788-95. PubMed ID: 26113241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.